| You are here: Home: BCU 1|2004: Saul E Rivkin, MD: Select publications
Select publications
Capecitabine
Hudis CA. Single-agent vs combination therapy in advanced breast cancer: Potential roles of capecitabine. Oncology (Huntingt) 2002;16(10 Suppl 12):13-6. Abstract
Lauman MK et al. Effect of pyridoxine on the incidence of palmar plantar erythroderma (PPE) in patients receiving capecitabine. Proc ASCO 2001; Abstract 1565.
Lin EH et al. Celecoxib attenuated capecitabine induced hand-and-foot syndrome (HFS) and diarrhea and improved time to tumor progression in metastatic colorectal cancer (MCRC). Proc ASCO 2002;Abstract 2364.
Miles D et al. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 2002;7 Suppl 6:13-9. Abstract
O'Shaughnessy J et al.Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract
O'Shaughnessy JA et al. Randomized, open-label, Phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12(9):1247-54. Abstract
Reichardt P et al. Multicenter Phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14(8):1227-33. Abstract
Seidman AD et al. Single-agent capecitabine: A reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002;7 Suppl 6:20-8. Abstract
Talbot DC et al. Randomised, Phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86(9):1367-72. Abstract
|
